Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
NNC4004-0002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
NNC4004-0002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ACE-2016 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ACE-2016: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
JSKN-022 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
JSKN-022: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NA-841 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
NA-841: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Morphine-6-glucuronide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Morphine-6-glucuronide: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
EPC-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
EPC-002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Hepatic Carcinoma Vaccine(WestGene) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Hepatic Carcinoma Vaccine(WestGene): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, an
9 min read
SY-007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
SY-007: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NEOG-100 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
NEOG-100: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ICF001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ICF001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Semaglutide (Terrestrial) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Semaglutide (Terrestrial): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
REGN-9533 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
REGN-9533: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.